Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Post by gainwidpatienceon Apr 23, 2020 11:57pm
336 Views
Post# 30947935

Get ready folks - LBL

Get ready folks - LBL

https://www.afr.com/companies/healthcare-and-fitness/mesoblast-s-covid-19-treatment-shows-positive-signs-20200424-p54muq?&utm_source=twitter&utm_medium=social&utm_campaign=nc&eid=socialn:twi-14omn0055-optim-nnn:nonpaid-27/06/2014-social_traffic-all-organicpost-nnn-afr-o&campaign_code=nocode&promote_channel=social_twitter

 

Listed biotech company Mesoblast says it is seeing positive signs for the use of its stem cell therapy in treating critically ill COVID-19 patients.

The company said 83 per cent of ventilator-dependent patients with a high risk of mortality who received its stem cell treatment have survived during early compassionate usage in New York's Mount Sinai hospital.

<< Previous
Bullboard Posts
Next >>